The Effect of Antenatal Neuroprotective Magnesium Sulfate Treatment on Cerebral Oxygenation in Preterm Infants.

Author(s) Bekmez, B.Ozer; Oğuz, Y.; Kutman, H.Gözde Kan; Uygur, D.; Canpolat, F.Emre; Oğuz, S.Suna; Tayman, C.
Journal Am J Perinatol
Date Published 2020 Mar 06

OBJECTIVE:  Antenatal magnesium sulfate (MgSO) treatment is associated with reduced risk of cerebral palsy in preterm infants. We aimed to investigate whether this treatment leads to any alterations on cerebral hemodynamics which could be detected by near-infrared spectroscopy (NIRS) readings in early postnatal life.

STUDY DESIGN:  Infants with gestational ages (GAs) ≤ 32 weeks were divided into two groups regarding their exposure to antenatal neuroprotective MgSO treatment or not. NIRS monitoring was performed to all infants, and readings were recorded for 2 hours each day during the first 3 days of life. The primary aim was to compare regional cerebral oxygen saturation (rcSO) and cerebral fractional tissue oxygen extraction (cFTOE) between the groups.

RESULTS:  Sixty-six infants were exposed to antenatal MgSO, while 64 of them did not. GA and birth weight were significantly lower in the treatment group ( < 0.01). No difference was observed in rcSO and cFTOE levels in the first, second, and the third days of life ( > 0.05). An insignificant reduction in severe intraventricular hemorrhage rates was observed (8 vs. 15%,  = 0.24).

CONCLUSION:  We could not demonstrate any effect on cerebral oxygenation of preterm infants in early postnatal life that could be attributed to antenatal neuroprotective MgSO treatment. Future studies are warranted to clarify the exact underlying mechanisms of neuroprotection.

DOI 10.1055/s-0040-1705148
ISSN 1098-8785
Citation Am J Perinatol. 2020.

Related Applications, Forms & Industries